MESO vs PFE: fair value comparison
Mesoblast Limited and Pfizer Inc. · Updated 2026-10-19
MESO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, MESO currently ranks higher by quality score.
| MESO | PFE | |
|---|---|---|
| Verdict | Awaiting full valuation | Overvalued |
| Last price | $13.28 | $28.28 |
| 12-month range | $13.19–$20.96 | $23.67–$29.58 |
| Rank by discount to fair value | — | #84 of 108 Healthcare |
| Rank by quality score | #105 of 301 Healthcare | #106 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: MESO fair value analysis · PFE fair value analysis